Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Christina Ravera"'
Autor:
Christina Ravera, Horst Schran, Wilson H. Miller, John J. Seaman, Andrej Skerjanec, Chyi-Hung Hsu, Felix Waldmeier, Pierre Major, James R. Berenson
Publikováno v:
The Journal of Clinical Pharmacology. 43:154-162
An open-label pharmacokinetic and pharmacodynamic study of zoledronic acid (Zometa) was performed in 19 cancer patients with bone metastases and known, varying levels of renal function. Patients were stratified according to creatinine clearance (CLcr
Autor:
Francois Legay, Sonia Gauron, Christina Ravera, Fabienne Deckert, Ghislaine Gosset, Ulrike Pfaar, Hansjörg Wiegand, Horst Schran
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 30:897-911
Zoledronic acid is a new, highly potent bisphosphonate drug under clinical evaluation. A radioimmunoassay has been developed to determine zoledronic acid concentration in human serum, plasma, and urine. The assay utilizes rabbit polyclonal antisera a
Autor:
Horst Schran, Michael Copeman, Serge Cremers, Andrew W. Roberts, Nola Kennedy, Christina Ravera, Sanela Bilic, Andrew Spencer, Teresa Neeman, Kevin Lynch
Publikováno v:
BMC Clinical Pharmacology
Background Cases of impaired renal function have been reported in patients who had been treated with both zoledronic acid and thalidomide for myeloma. Hence, we conducted a safety study of zoledronic acid and thalidomide in myeloma patients participa
Autor:
R. Hoekstra, Sujata Vaidyanathan, Allan T. van Oosterom, Andre S. T. Planting, Isaiah J. Fidler, Jaap Verweij, Corazon D. Bucana, Ate van der Gaast, Christina Ravera, Herlinde Dumez, Kurt C. Sizer, Ferry A.L.M. Eskens, Gerda de Heus
Publikováno v:
Clinical Cancer Research, 11(19), 6908-6915. American Association for Cancer Research Inc.
Purpose: This phase I study was conducted to assess the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor tyrosine kinase inhibitor PKI166 in patients with advanced solid malignancies. Expe
Autor:
Robert Vescio, Peiming Ma, James R. Berenson, Susan Goodin, Horst Schran, Regina A. Swift, Chen Tianling, Andrej Skerjanec, Patricia LoRusso, Alicia Gilchick, Christina Ravera, John J. Seaman, Fabienne Deckert
Publikováno v:
Journal of clinical pharmacology. 42(11)
The pharmacokinetics, pharmacodynamics, and safety of zoledronic acid (Zometa), a new-generation bisphosphonate, were evaluated in 36 patients with cancer and bone metastases. Zoledronic acid (by specific radioimmunoassay) and markers of bone turnove
Publikováno v:
Bone. 42:S107-S108
Autor:
Horst Schran, Sonia Gauron, Andrej Skerjanec, James R. Berenson, Pierre Major, Robert Vescio, Christina Ravera, Sanela Bilic
Publikováno v:
Journal of Urology. 179:181-181
Publikováno v:
Blood. 104:4939-4939
Background: Zoledronic acid is a new-generation bisphosphonate with demonstrated efficacy and safety in the treatment of bone lesions in patients with multiple myeloma and solid tumors using a monthly regimen of 4 mg infused over 15 minutes. This pha